In the past week, two newly listed companies—one in biotech and another in cybersecurity—saw insiders pour over $98 million into their shares, signaling strong confidence in their markets. A coal miner also attracted attention as a director increased their stake, joining several chief executives who have made similar moves.

Parkman Healthcare Partners LLC purchased 76,125 shares of Vera Therapeutics in the first quarter, investing approximately $1,829,000. This acquisition reflects growing institutional interest, with other major players also revising their stakes in the company.

Allostery Investments LP made a notable move in the biotech sector by acquiring 4,750 shares of Legend Biotech, valued at about $161,000. This transaction, carried out during the first quarter, aligns with ongoing institutional interest in Legend Biotech Corporation.

ADAR1 Capital Management LLC recently scaled down its investment in Mineralys Therapeutics, Inc. by 68.7%, selling over half a million shares. The firm now holds 263,425 shares, valued at approximately $4.18 million at the close of the first quarter.

Braidwell LP has acquired 140,000 shares of Beta Bionics, Inc., worth approximately $1.7 million. An SEC filing confirms that the purchase gives Braidwell LP about 0.32% ownership of the company, indicating growing investor interest in biotech innovations.

ADMA Biologics, Inc. has caught the attention of investors intrigued by its optimistic valuation metrics and forward-looking prospects. A recent bullish thesis proposes that the stock’s financial ratios, along with expert commentary, could be key indicators of future growth.

Swiss National Bank recently reduced its holding in Rhythm Pharmaceuticals by a modest 900 shares during the first quarter, as disclosed in a new SEC filing. Despite the small adjustment, the bank retains a significant position in the company.

PNC Financial Services Group has quietly pared back its stake in Vericel Corporation. A recent SEC filing shows the bank sold 378 shares in the first quarter—an 8.2 percent trim that leaves it holding 4,251 shares of the NASDAQ-listed biotech firm.

Zacks Small Cap has inched its third-quarter 2025 earnings forecast for Longeveron Inc. higher, trimming the biotech’s expected loss to 26 cents a share. The research note, issued Aug. 14 by analyst B. Sorensen, offers a modest but notable vote of confidence in the Nasdaq-listed company.